What Analysts Are Recommending for Pfizer and Other Major Oncology Players in 2016
Among the 27 brokerage firms surveyed, 57.7% gave Pfizer’s stock a “buy” recommendation, while 42.3% gave a “hold” recommendation. None has given a “sell.”
Medivation has added its robust research pipeline with two promising investigational drugs, Talazoparib and Pidilizumab, to Pfizer’s oncology portfolio.
Pfizer (PFE) is confident that Xtandi will be able to penetrate a much larger market if the drug is approved for early-stage prostate cancer.
On June 6, Pfizer and Merck announced positive results from a Phase 2 study testing Avelumab as a therapy for previously treated Merkel cell carcinoma.
On September 28, 2016, Pfizer (PFE) announced the completion of its acquisition of Medivation for around $14 billion.
On January 27, 2012, the FDA approved Pfizer’s (PFE) Inlyta as a second-line therapy for patients suffering from advanced kidney cancer or RCC.
On January 26, 2006, the FDA approved Pfizer’s (PFE) Sutent as a therapy for patients suffering from GIST (gastrointestinal stromal tumors).
Pfizer (PFE) expects Ibrance to pose strong competition to upcoming CDK 4/6 inhibitor therapies from Novartis (NVS) and Eli Lilly (LLY).
On August 26, 2011, the FDA approved Pfizer’s (PFE) Xalkori for patients suffering from late-stage NSCLC and who express abnormal ALK gene.
On October 21, 2016, Pfizer was trading at a forward PE multiple of about 11.4x. Since January 1, 2016, it has traded at PE multiples of 11.2x–13.5x.
Wall Street projected a rise in Becton, Dickinson and Company’s (BDX) adjusted net profit margins. The margins are expected to come in at ~$453 million.
Wall Street estimated that Becton, Dickinson and Company’s fiscal 4Q16 revenue will be ~$3.22 billion—growth of around 5.2% on a YoY basis.
Becton, Dickinson and Company (BDX) is set to release its 4Q16 earnings results on November 3. Investors can get exposure to the company through USMV.
Based on 20 brokerage firms in a Bloomberg survey, 75% rated Abbott Laboratories a “buy,” 25% rated it a “hold,” and none rated it a “sell.”
In 2016, Abbott Laboratories expects its EPS to be $2.19–$2.21. It narrowed its fiscal 2016 EPS guidance compared to the previous guidance of $2.14–$2.24.
Abbott Laboratories’ Medical Device segment contributed about 24.7% of its total revenues of ~$5.3 billion in 3Q16—an ~6.5% YoY increase in 3Q16.
Abbott Laboratories (ABT) reported ~$5.3 billion in total revenues in 3Q16. Of that, ~$1.75 billion came from the Nutrition segment’s sales.
On October 19, Abbott Laboratories (ABT) released its 3Q16 earnings. After the announcement, its share price fell ~2% from $41.2 on October 18, 2016.
Bristol-Myers Squibb’s (BMY) Neuroscience and Immunoscience segments see much lower sales than the company’s other segments.
Bristol-Myers Squibb’s (BMY) Virology segment is the company’s second-largest revenue contributor, responsible for ~28% of the company’s total revenues.